PEARLDIFER
A Phase II study of pemigatinib after SBRT(Stereotactic Body Radiation Therapy) or other minimally invasive technique as definitive organpreserving therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements
DEMAND
Randomisierte, zweiarmige nicht vergleichende Phase II Studie zur Wirksamkeit von Atezolizumab und Bevacizumab gefolgt von selektiver TACE nur bei Bedarf im Falle des Auftretens von Krankheitsprogression oder initial synchroner Behandlung mit TACE und Atezolizumab und Bevacizumab bei der Behandlung von Patienten mit nicht resektablem hepatozellulärem Karzinom
CO44668 IMbrave152
a phase III, randomized, double-blind, placebo-controlled study evaluating atezolizumab and bevacizumab, with or without tiragolumab, in patients with untreated locally advanced or metastatic hepatocelluar carcinoma
ABC HCC
The ABC-HCC Trial:A Phase IIIb, randomized, multicenter, opern-label trial of Atezolizumab plus bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage HepatoCelluar Carcinoma
COLOPREDICT PLUS
RegisterRetro- und prospektive Erfassung der Rolle von MSI und KRAS für die Prognose beim Kolonkarzinom im Stadium II + III
ACO/ARO/AIO 18.2
Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized phase III trial of the German Rectal Cancer Study Group
BERING-CRC NIS
BRAF Inhibitor Encorafenib and Cetuximab Real Life Investigation of next generation CRC Treatment
BNT 122-01
A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection
Stand 04.07.2024